Antidiabetic Drugs Classification

Antidiabetic drugs lower blood glucose through different mechanisms, including reducing hepatic glucose production, increasing insulin secretion or sensitivity, enhancing incretin activity, increasing urinary glucose excretion, and replacing insulin.

Major Category	Drug Class / Subclass	Important Examples	Primary Mechanism of Action	Main Pharmacological Effect	Hypoglycemia Risk	Effect on Weight	Route	Important Adverse Effects / Notes
1. Insulin & Insulin Analogues	Rapid-acting insulin	Insulin lispro, Insulin aspart, Insulin glulisine	Replaces endogenous insulin; ↑ glucose uptake and ↓ hepatic glucose production	Rapid reduction of blood glucose, especially postprandial	High	↑	SC	Hypoglycemia, weight gain, injection-site reactions
	Short-acting insulin	Regular human insulin	Activates insulin receptors → ↑ glucose uptake and ↓ hepatic glucose output	Controls fasting and postprandial glucose	High	↑	SC, IV	Hypoglycemia, weight gain
	Intermediate-acting insulin	NPH insulin	Provides prolonged insulin replacement	Basal glucose control	High	↑	SC	Hypoglycemia, weight gain
	Long-acting insulin	Insulin glargine, Insulin detemir	Provides relatively sustained basal insulin activity	Basal glucose control	High	↑	SC	Hypoglycemia, weight gain
	Ultra-long-acting insulin	Insulin degludec, Insulin glargine U-300	Very prolonged basal insulin action	Basal glucose control	High	↑	SC	Hypoglycemia, weight gain
	Premixed insulin preparations	NPH/regular, insulin lispro protamine/lispro, insulin aspart protamine/aspart	Combination of basal/intermediate and prandial insulin activity	Basal + mealtime control	High	↑	SC	Hypoglycemia, weight gain
2. Insulin Secretagogues	Sulfonylureas – 1st generation	Tolbutamide, Chlorpropamide	Close ATP-sensitive K⁺ channels in pancreatic β-cells → depolarization → ↑ insulin release	↑ Insulin secretion	High	↑	Oral	Hypoglycemia, weight gain; older drugs are less commonly used
	Sulfonylureas – 2nd generation	Glipizide, Glimepiride, Gliclazide, Glyburide/Glibenclamide	Stimulate pancreatic β-cell insulin secretion	↑ Insulin secretion	High	↑	Oral	Hypoglycemia, weight gain
	Meglitinides / Glinides	Repaglinide, Nateglinide	Short-acting stimulation of β-cell insulin secretion	Mainly reduces postprandial glucose	Moderate–High	↑	Oral	Hypoglycemia, weight gain
3. Insulin Sensitizers	Biguanide	Metformin	↓ Hepatic gluconeogenesis; ↑ insulin sensitivity and peripheral glucose uptake	↓ Hepatic glucose production	Low when used alone	Neutral / modest ↓	Oral	GI upset; vitamin B12 deficiency can occur; lactic acidosis is rare but serious
	Thiazolidinediones (TZDs)	Pioglitazone, Rosiglitazone	Activate PPAR-γ → alter gene transcription → ↑ insulin sensitivity	↑ Peripheral insulin sensitivity	Low when used alone	↑	Oral	Edema, weight gain, heart-failure risk; fractures
4. Carbohydrate Absorption Inhibitors	α-Glucosidase inhibitors	Acarbose, Miglitol	Inhibit intestinal α-glucosidases → delay carbohydrate digestion and glucose absorption	↓ Postprandial glucose	Low when used alone	Neutral / possible slight ↓	Oral	Flatulence, abdominal discomfort, diarrhea
5. Incretin-Based Drugs	GLP-1 receptor agonists	Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Semaglutide	Activate GLP-1 receptors → glucose-dependent ↑ insulin, ↓ glucagon, delayed gastric emptying, ↑ satiety	↓ Glucose; weight loss	Low when used alone	↓	Mainly SC; some oral formulations exist	Nausea, vomiting, diarrhea; class-specific precautions
	Dual GIP/GLP-1 receptor agonist	Tirzepatide	Activates GIP and GLP-1 receptors	Powerful glucose lowering and weight reduction	Low when used alone	↓↓	SC	GI adverse effects; hypoglycemia risk increases with insulin/secretagogues
	DPP-4 inhibitors	Sitagliptin, Saxagliptin, Linagliptin, Alogliptin	Inhibit DPP-4 → prolong endogenous GLP-1/GIP activity → ↑ glucose-dependent insulin and ↓ glucagon	Modest glucose lowering	Low	Neutral	Oral	Nasopharyngitis, GI effects; class-specific cardiovascular considerations
6. Renal Glucose-Lowering Drugs	SGLT2 inhibitors	Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin	Inhibit renal SGLT2 → ↓ proximal tubular glucose reabsorption → ↑ urinary glucose excretion	↓ Blood glucose; natriuresis	Low when used alone	↓	Oral	Genital mycotic infections, volume depletion; ketoacidosis can occur
7. Amylin-Based Therapy	Amylin analogue	Pramlintide	Mimics amylin → ↓ glucagon secretion, slows gastric emptying, increases satiety	↓ Postprandial glucose	Low alone; higher with insulin	↓	SC	Nausea; hypoglycemia particularly with concomitant insulin
8. Bile Acid Sequestrants	Bile acid sequestrant	Colesevelam	Mechanism for glucose lowering is not completely established; affects bile acid metabolism	Modest glucose lowering	Low	Neutral / possible slight ↑	Oral	Constipation, GI effects; drug interactions
9. Dopamine Agonists	Dopamine D2 agonist	Bromocriptine-QR	Modulates hypothalamic dopaminergic activity; improves metabolic regulation	Modest glucose lowering	Low	Neutral / possible ↓	Oral	Nausea, dizziness, orthostatic symptoms
10. Other / Less Common Agents	Glucose-lowering agents with limited use	Various agents depending on country/approval	Varies	Varies	Varies	Varies	Varies	Availability and clinical use vary by country

The classification reflects the major contemporary glucose-lowering drug groups, while also retaining important pharmacology classifications such as secretagogues, sensitizers, carbohydrate-absorption inhibitors, and insulin therapy.